Abstract
Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 634-646 |
| Number of pages | 13 |
| Journal | Photomedicine and Laser Surgery |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- depression
- low-level laser therapy
- randomized controlled trial
ASJC Scopus subject areas
- Biomedical Engineering
- Radiology Nuclear Medicine and imaging
Cite this
Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial. / Cassano, Paolo; Petrie, Samuel R.; Mischoulon, David; Cusin, Cristina; Katnani, Husam; Yeung, Albert; De Taboada, Luis; Archibald, Abigal; Bui, Eric; Baer, Lee; Chang, Trina; Chen, Justin; Pedrelli, Paola; Fisher, Lauren; Farabaugh, Amy; Hamblin, Michael R.; Alpert, Jonathan E.; Fava, Maurizio; Iosifescu, Dan V.
In: Photomedicine and Laser Surgery, Vol. 36, No. 12, 01.12.2018, p. 634-646.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial
AU - Cassano, Paolo
AU - Petrie, Samuel R.
AU - Mischoulon, David
AU - Cusin, Cristina
AU - Katnani, Husam
AU - Yeung, Albert
AU - De Taboada, Luis
AU - Archibald, Abigal
AU - Bui, Eric
AU - Baer, Lee
AU - Chang, Trina
AU - Chen, Justin
AU - Pedrelli, Paola
AU - Fisher, Lauren
AU - Farabaugh, Amy
AU - Hamblin, Michael R.
AU - Alpert, Jonathan E.
AU - Fava, Maurizio
AU - Iosifescu, Dan V.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
AB - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
KW - depression
KW - low-level laser therapy
KW - randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85053529628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053529628&partnerID=8YFLogxK
U2 - 10.1089/pho.2018.4490
DO - 10.1089/pho.2018.4490
M3 - Article
VL - 36
SP - 634
EP - 646
JO - Photomedicine and Laser Surgery
JF - Photomedicine and Laser Surgery
SN - 1549-5418
IS - 12
ER -